Lifshitz Law PLLC Announces Investigations of Archer Aviation, Inc. (NYSE: ACHR), PureCycle Technologies, Inc. (NASDAQ: PCT), Medical Properties Trust, Inc. (NYSE: MPW), and Kenvue Inc. (NYSE: KVUE)

NEW YORK, NY / ACCESSWIRE / October 15, 2023 /

Archer Aviation, Inc. (NYSE:ACHR)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements and/or failed to disclose that: (i) the Company relied on heavily edited videos of earlier flights to exaggerate the amount of flight testing it had actually performed and the sophistication of its eVTOL aircraft; (ii) the Company had misrepresented the nature and profitability of its business partnerships, (iii) the Company was unlikely to secure FAA certification in the timeframe it had represented to investors, thereby delaying the start of mass production of its aircraft for commercial sales; (iv) accordingly, the Company had overstated its financial position and/or prospects; (v) all of the foregoing, once revealed, was likely to subject the Company to significant financial and/or reputational harm; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

If you are an ACHR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

PureCycle Technologies, Inc. (NASDAQ:PCT)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company failed to disclose to investors: (i) that the Ironton Facility experienced a full plant power outage on August 7, 2023; (ii) that there was a risk of additional failures resulting from the August 7, 2023 power outage; and (iii) that, as a result of the foregoing, the Company's positive statements about its business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you are a PCT investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

Medical Properties Trust, Inc. (NYSE:MPW)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements and/or failed to disclose that: (i) the Recap Transaction was subject to regulatory approval and had in fact been placed on hold by the Department of Managed Health Care of the Health and Human Services Agency of the State of California; (ii) accordingly, MPW had misrepresented the regulatory process for the Recap Transaction's approval; (iii) as a result of the foregoing, MPW overstated the approval prospects and benefits of the Recap Transaction; and (iv) as a result, the Company's public statements regarding the Recap Transaction were materially false and misleading at all relevant times.

If you are a MPW investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

Kenvue Inc. (NYSE:KVUE)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Registration Statement issued in connection with Kenvue's initial public offering contained false and/or misleading statements and/or failed to disclose that: (i) Kenvue faces potential headwinds as a result of confirmed concerns about the efficacy of phenylephrine, which it knew or should have known; (ii) Kenvue did not discuss risks relating to the efficacy of phenylephrine in its IPO, the utility of which had been questioned since at least 2007; (iii) while the Company disclosed risks relating to litigation, it did not disclose specific risk relating to potential litigation arising from adverse findings on the efficacy of phenylephrine; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times and negligently prepared.

If you are a KVUE investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

ATTORNEY ADVERTISING.© 2023 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:

Joshua M. Lifshitz, Esq.

Lifshitz Law PLLC
Phone: 516-493-9780

Facsimile: 516-280-7376

Email: jlifshitz@lifshitzlaw.com

SOURCE: Lifshitz Law Firm, P.C.